Alumis Inc. (ALMS)
NASDAQ · Healthcare
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $3.74B
- P/E ratio
- —
- EPS
- —
- Volume
- 673,123
- 52-week high
- —
- 52-week low
- —
- Open
- $28.55
- Day high
- $29.57
- Day low
- $27.92
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | $24.05M | -$243.33M | -$2.86 |
| 2024 | — | -$294.23M | -$10.38 |
| 2023 | — | -$154.99M | -$72.08 |
About Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
- CEO
- Martin Babler
- Employees
- 223
- Country
- US
- IPO date
- Jun 28, 2024
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Alumis Inc.'s stock price today?
- ALMS is trading at $27.98 as of Jul 20, 2026.
- What is Alumis Inc.'s market cap?
- Alumis Inc. (ALMS) has a market capitalization of $3.74B.
- Does Alumis Inc. pay a dividend?
- Alumis Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Alumis Inc. in?
- Alumis Inc. operates in the Healthcare sector.